Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Rating of “Buy” from Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have received an average recommendation of “Buy” from the twelve analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $12.78.

A number of research analysts have recently commented on the company. Wall Street Zen cut Shattuck Labs from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. TD Cowen upgraded shares of Shattuck Labs to a “strong-buy” rating in a report on Monday, August 24th. Raymond James Financial started coverage on shares of Shattuck Labs in a research note on Monday, August 24th. They issued a “strong-buy” rating and a $18.00 price target on the stock. Leerink Partners began coverage on shares of Shattuck Labs in a research report on Monday, July 20th. They issued an “outperform” rating and a $16.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Shattuck Labs in a research note on Friday, July 24th. They issued an “overweight” rating and a $10.00 target price on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of STTK. Squarepoint Ops LLC raised its holdings in shares of Shattuck Labs by 129.6% in the second quarter. Squarepoint Ops LLC now owns 71,547 shares of the company’s stock valued at $497,000 after acquiring an additional 40,385 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in Shattuck Labs in the second quarter worth approximately $26,025,000. Wellington Management Group LLP purchased a new stake in Shattuck Labs during the second quarter worth $12,269,000. Bank of America Corp DE bought a new stake in Shattuck Labs during the 2nd quarter valued at $319,000. Finally, Hsbc Holdings PLC bought a new stake in Shattuck Labs during the 2nd quarter valued at $312,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

Shares of Shattuck Labs stock opened at $6.84 on Friday. The stock has a market cap of $686.46 million, a price-to-earnings ratio of -13.41 and a beta of 1.09. The stock has a 50 day moving average price of $6.92 and a 200-day moving average price of $6.53. Shattuck Labs has a one year low of $1.70 and a one year high of $8.33.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). Sell-side analysts predict that Shattuck Labs will post -0.45 earnings per share for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create bifunctional fusion proteins that combine immune-cell activation with the targeted blocking of immune-suppressive pathways.

Shattuck’s lead investigational programs are intended to stimulate antitumor immune responses within the tumor microenvironment.